COG AAML1321/Novartis CAMN107A2203: A multi-center, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients with newly diagnosed Ph+ chronic myelogenous leukemia (CML) i

  • Hijiya, Nobuko (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/4/149/30/17

Funding

  • Children's Hospital of Philadelphia
  • Novartis Pharmaceuticals Corporation